

## **NTC CLOSES A DEAL WITH BRUNO FARMACEUTICI FOR THE DEVELOPMENT OF A NEW SOLUTION TO TREAT EXTERNAL AND MEDIUM OTITIS WITH TYMPANOSTOMY IN CHILDREN.**

*Milan, February 26<sup>th</sup> 2019* – NTC Srl, an Italian pharmaceutical company with significant expertise in research and development in ophthalmology, announces today a commercial partnership with Bruno Farmaceutici S.p.A., a pharmaceutical player with relevant expertise in ENT (Ear, Nose and Throat). The deal is about a cooperation for the international development of a new product consisting in a fixed combination of a quinolone antibiotic with an anti-inflammatory steroid in solution, for otologic use.

This new drug will represent a step forward in the treatment of medium and external otitis, particularly in kids.

Over 85 percent of children under 3 years old develop at least one episode of acute otitis media and in about 1/3 of the cases there is significant recurrence, especially in children in the first 2 years of life. External otitis is also very common (25-50 percent of ear phlogistic diseases), especially in the summer months due to frequent contact with water and in 98 percent of cases it is of bacterial origin.

Given the incidence of the disease, nursing pediatric otitis is often a huge problem for both children and their families: the child feels pain, doesn't sleep, moans and, in addition, otitis is often a recurrent disease. Several are the treatments used: sometimes doctors combine the topical use of the antibiotic plus anti-inflammatory medicine with a concomitant systemic use of antibiotic drugs.

This new product means to offer to pediatricians, ENTs specialists and general practitioners an innovative therapeutic solution supported by an unprecedented wide clinical research program conducted with an evidenced-based approach.

"We are really pleased with this agreement. We bring our clinical expertise and our knowledge in ENT into this innovative development. The new product will mean a strategic addition to our existing portfolio to help us to further and act as leader in this therapeutic area in Italy", said **Bruno Farmaceutici's General Manager, Vincenzo Bruno**. "We started a profitable cooperation with NTC, a company that is strongly active in the research and development, from whom we did already successfully license a number of products in the past few years."

"We are delighted to strengthen our relationship with Bruno Farmaceutici, this partnership gives value to NTC strong commitment to carry on wide clinical research and development programs to study better products with tangible novel therapeutic evidences aimed to reduce the antibiotic exposure and, consequently, the antibiotic resistance in children", added Riccardo **Carbucchio, NTC's President and CEO**. "This is our focus in Italy and worldwide where we operate through several strategic and commercial partnerships. Bruno



Farmaceutici will be our strong partner in Italy while we plan to out license this innovative drug for otitis externa and media in the rest of the world”.

Both companies, NTC and Bruno Farmaceutici, intend to give an effective and direct contribution to the development of new products with the view of satisfying unmet medical and patient’s needs through evidence-based scientific data and high-quality therapeutic solutions.

### **NTC Srl**

NTC is a pharmaceutical company headquartered in Milan, Italy, with commercial activities in over 70 countries, and operates in the international research, development, registration and marketing of drugs, medical devices and food supplements mainly in the ophthalmology area, but also in pediatric area and gastro-intestinal metabolism.

NTC offers its business partners, currently more than 200 in the world, innovative products that follow high quality standards.

For more information: <http://www.ntcpharma.com>

### **BRUNO FARMACEUTICI SpA**

Bruno Farmaceutici was founded in 1996 with the acquisition of a branch of the multinational Aventis. Over the years the company has embarked on a development path in various therapeutic areas, increasing its portfolio.

These activities, together with the acquisition of Safilens, a leading ophthalmic pharmaceutical company in the reference market, and the purchase of Merck Serono's cardiac metabolic line, have made Bruno Farmaceutici a young and emerging company present both in the Italian and international markets.

For more information: [www.bruno.org](http://www.bruno.org)